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Abstract 
Background: Selecting the most beneficial treatment regimens for colorectal cancer (CRC) 
patients remains challenging due to a lack of prognostic markers. Members of the Myosin family, 
proteins recognized to play a major role in trafficking and polarization of cells, have recently been 
reported to be closely associated with several types of cancer and might thus serve as potential 
prognostic markers in the context of CRC.  
Methods: We used a previously established meta-analysis of publicly available gene expression 
data to analyse the expression of different members of the Myosin V family, namely MYO5A, 5B, 
and 5C, in CRC. Using laser-microdissected material as well as tissue microarrays from paired 
human CRC samples, we validated both RNA and protein expression of MYO5B and its known 
adapter proteins (RAB8A and RAB25) in an independent patient cohort. Finally, we assessed the 
prognostic value of both MYO5B and its adapter-coupled combinatorial gene expression 
signatures. 
Results: The meta-analysis as well as an independent patient cohort study revealed a 
methylation-independent loss of MYO5B expression in CRC that matched disease progression. 
Although MYO5B mutations were identified in a small number of patients, these cannot be solely 
responsible for the common down-regulation observed in CRC patients. Significantly, CRC 
patients with low MYO5B expression displayed shorter overall, disease- and metastasis-free 
survival, a trend that was further reinforced when RAB8A expression was also taken into account. 
Conclusions: Our data identifies MYO5B as a powerful prognostic biomarker in CRC, especially 
in early stages (stages I and II), which might help stratifying patients with stage II for adjuvant 
chemotherapy.  
 
